Thomas J. Herzog, MD

Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381

Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512

Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42

Jackson A.;Eisenhauer E.;Herzog T. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346

Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271

Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589

Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625

Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525

Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254